Frazier Healthcare Partners said Feb. 15 that Dr. Krishna Polu has joined the Life Sciences operating professional team as an entrepreneur-in-residence with Hawkeye Therapeutics. Dr. Polu previously served as chief medical officer at Raptor Pharmaceuticals until its acquisition by Horizon Pharmaceuticals in 2016.
MENLO PARK, Calif.–(BUSINESS WIRE)–Frazier Healthcare Partners, a leading provider of growth and venture capital to healthcare companies, has announced that Krishna Polu, M.D. has joined the Life Sciences operating professional team as an Entrepreneur-in-Residence with Hawkeye Therapeutics, a Frazier-founded search company focused on in-licensing and developing high-quality assets from pharmaceutical companies.
Dr. Polu is an experienced clinical development executive with a track record of pipeline advancement and drug approvals across therapeutic areas. Prior to joining Frazier, he served as Chief Medical Officer at Raptor Pharmaceuticals until its acquisition by Horizon Pharmaceuticals in 2016 for $800 million. He also previously served as Chief Medical Officer at CytomX Therapeutics, and held senior level positions in clinical development at Affymax and Amgen. He holds a B.A. from Stanford University and an M.D. from the University of Texas Health Science Center, San Antonio.
“We are delighted to have Krishna as part of the Frazier Life Sciences team,” stated Jamie Topper, managing general partner. “He brings his extensive translational, clinical and regulatory development expertise to our active company creation efforts.”
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $3.0 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.
For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.
About Hawkeye Therapeutics
Headquartered in San Diego, Calif., Hawkeye Therapeutics licenses and develops high-quality assets from pharmaceutical companies. For more information, visit the company’s website at www.hawkeyerx.com.